MedTrace Logo

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

NCT07634471 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 960

Last updated 2026-08-07

No results posted yet for this study

Summary

Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy.

The goals of this study are to learn:

* About the safety of MK-1045 and rituximab, and if people tolerate them when given together
* If people who receive MK-1045 and rituximab have the cancer go away
* If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)

Conditions

Interventions

BIOLOGICAL

MK-1045

Intravenous (IV) infusion

BIOLOGICAL

Rituximab

IV infusion

BIOLOGICAL

Rituximab biosimilar

IV infusion

DRUG

Bendamustine

IV infusion

DRUG

Cyclophosphamide

IV infusion

DRUG

Vincristine

IV infusion

DRUG

Prednisone

Per approved product label

DRUG

Prednisolone

Per approved product label

DRUG

Doxorubicin Hydrochloride

IV infusion

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-22
Primary Completion
2032-07-23
Completion
2035-07-23
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Israel
  • Spain
  • Taiwan
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07634471 on ClinicalTrials.gov